Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

معايير اعتماد المستشفيات المعدلة في لبنان- كانون الأول 2022

 
The health care system has been adversely impacted by multi-dimensional crisis, including the economic collapse, COVID-19 pandemic, Beirut Port explosion, and socio-political unrest. The unavailability and increased cost of basic commodities such as fuel and electricity has further challenged an overburdened system.

Maintaining the quality of care and patient safety in the midst of the challenges facing health institutions remains a priority and constitutes a guarantee for quality services. Maintaining quality standards saves lives, contributes to alleviating the financial burden, and reserves the position of high-level health services on the health map in the region.

After a long period of pausing the Accreditation process in Lebanon, the Ministry of Public Health is working again to revive this very important project that has started since 2001 and was updated and improved over time.  For the purpose of improving and updating the current hospital accreditation system in Lebanon, the Ministry of Public Health aimed to revise and develop new Lebanese hospital accreditation standards according to latest evidence and international best practices, in compliance with International Society for Quality in Healthcare (ISQua) requirements.

Since January 2022, and under the great support of AFD (Agence Française de Développement), a cooperation agreement was signed between the Lebanese Ministry of Public Health (MOPH) and the French Health Authority (HAS) for a new iteration of the accreditation project in collaboration, in collaboration with the Ecole Supérieure des Affaires (ESA) as a local counterpart to ensure logistical, educational and administrative support. The governance of the program kept the current organizational structure: the Comité National d’Accréditation Hospitalière (CNAH) and the Comité Technique d’Accréditation Hospitalière (CTAH). In addition to a new unit created at the Ministry of Health as the operational structure, the Bureau d’Accréditation et d’Evaluation (BAE) to follow-up on the implementation of the project. The revision of the procedure and the manual was performed by local and international experts.

The Ministry of Public Health announces the official publication of the new accreditation standards manual for hospitals. The present version has been updated to include “intent”  sections for each standard, aiming at allowing hospitals better comprehend and meet the requirements of the standards.

For any inquiry, please contact the Accreditation office at the MOPH by email on:
accreditation@moph.gov.lb or ritafreiha@hotmail.com
 
    ...
    27
    ...
ATC Name B/G Ingredients Dosage Form Price
L01DC01 BLEO-CELL G Bleomycin (sulfate) - 15mg 15mg Injectable powder for solution 3,817,857 L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution 2,109,833 L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution L.L
L01FX07 BLINCYTO BioTech Blinatumomab - 35mcg 35mcg Injectable lyophilised powder for solution+stabilizer 239,128,127 L.L
L01FX07 BLINCYTO BioTech Blinatumomab - 35mcg 35mcg Injectable lyophilised powder for solution+stabilizer L.L
C07AB03 BLOKIUM 100MG G Atenolol - 100mg 100mg Tablet 377,620 L.L
C07AB03 BLOKIUM 50MG G Atenolol - 50mg 50mg Tablet 186,794 L.L
C09CA06 BLOPRESS B Candesartan cilexetil - 8mg 8mg Tablet 806,306 L.L
C09CA06 BLOPRESS B Candesartan cilexetil - 16mg 16mg Tablet 1,040,134 L.L
C09DA06 BLOPRESS PLUS 16MG B Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 1,040,134 L.L
C09DA06 BLOPRESS PLUS 8MG B Candesartan cilexetil - 8mg, Hydrochlorothiazide - 12.5mg Tablet 806,306 L.L
C07AB12 BLOVEK G Nebivolol HCl - 5mg Tablet 511,940 L.L
D01BA02 BODERM G Terbinafine HCl - 250mg 250mg Tablet 749,992 L.L
M05BA06 BONAFOR G Ibandronic acid (monosodium monohydrate) - 150mg 150mg Tablet, film coated 383,955 L.L
M05BA06 BONDRONAT B Ibandronic acid (monosodium monohydrate) - 6mg/6ml 6mg/6ml Injectable concentrated powder for solution 24,963,868 L.L
H05AA02 BONTEO BioTech Teriparatide - 20mcg/dose 20mcg/dose 17,383,843 L.L
M05BA06 BONVIVA B Ibandronic acid - 150mg 150mg Tablet, film coated 1,265,900 L.L
J07AJ51 BOOSTRIX B Diphteria toxoid purified - ?2.5Lf/0.5ml, Tetanus toxoid purified - ?5Lf/0.5ml, Bordetella Pertussis Antigens: toxoid - 8mcg/0.5ml, Bordetella Pertussis Antigens: filamentous haemagglutinin - 8mcg/0.5ml, Pertactine - 2.5mcg Al3+/0.5ml, Aluminium hydroxide - 0.3mg Al3+/0.5ml, Aluminium Phosphate - 0.2mg/0.5ml Injectable suspension 1,394,909 L.L
L01XG01 BORCADE G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 11,020,381 L.L
L01XG01 BORCADE G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 11,020,381 L.L
L01XG01 BORTEZOMIB ACCORD G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 13,007,658 L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution 14,169,600 L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution L.L
L01XG01 BORTEZOMIB PHARMINICIO G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 13,007,658 L.L
L01XG01 BORTEZOMIB SHILPA G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder 9,902,420 L.L
L01XG01 BORTEZOMIB SPC G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 15,743,401 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated 51,483,159 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated 51,483,159 L.L
    ...
    27
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026